Literature DB >> 22267099

Using the antinuclear antibody test to diagnose rheumatic diseases: when does a positive test warrant further investigation?

Elizabeth R Volkmann1, Mihaela Taylor, Ami Ben-Artzi.   

Abstract

The anti-nuclear antibody (ANA) test is ordered commonly as a screening test for rheumatic diseases. Although ANA positivity is highly sensitive for certain rheumatic diseases, the presence of ANA is nonspecific and can be associated with numerous nonrheumatic factors, including environmental exposures, malignancies, drugs, and infections. This article describes a practical approach for physicians when evaluating patients using a positive ANA test. In the absence of connective tissue disease symptoms, the ANA test has minimal clinical significance in diagnosing rheumatic diseases. Understanding how to use ANA test results appropriately may reduce unnecessary referrals and costly workups.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22267099     DOI: 10.1097/SMJ.0b013e31824551a1

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  3 in total

1.  Inappropriate use of commercial Antinuclear Antibody Testing in a community-based US hospital: a retrospective study.

Authors:  Abdul S Mohammed; Prajwal Boddu; David Mael; Mohammed Samee; Dana Villines
Journal:  J Community Hosp Intern Med Perspect       Date:  2016-09-07

2.  Anti-nuclear autoantibodies in the general German population: prevalence and lack of association with selected cardiovascular and metabolic disorders-findings of a multicenter population-based study.

Authors:  Manas K Akmatov; Nadja Röber; Wolfgang Ahrens; Dieter Flesch-Janys; Julia Fricke; Halina Greiser; Kathrin Günther; Rudolf Kaaks; Yvonne Kemmling; Bastian Krone; Jakob Linseisen; Christa Meisinger; Susanne Moebus; Nadia Obi; Carlos A Guzman; Karsten Conrad; Frank Pessler
Journal:  Arthritis Res Ther       Date:  2017-06-06       Impact factor: 5.156

3.  Serum Soluble Vascular Cell Adhesion Molecule-1 Overexpression Is a Disease Marker in Patients with First-Time Diagnosed Antinuclear Antibodies: A Prospective, Observational Pilot Study.

Authors:  Mara Oleszowsky; Matthias F Seidel
Journal:  Biomed Res Int       Date:  2018-02-01       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.